The Prevalence of SARS-CoV-2 Antibodies Within the Community of a Private Tertiary University in the Philippines: A Serial Cross Sectional Study

• Main Authors: Tanchanco, Lourdes S, Sy, Jenica Clarisse Y, Dy, Angel Belle C, Levantino, Myla D, Amit, Arianna Maever L, Wong, John, Angeles, Kirsten, Vergara, John Paul
• 格式: text
• 出版: Archīum Ateneo 2022
• 主題: immunoglobulin G antibody; SARS-CoV-2 antibody; SARS-CoV-2 vaccine; immunoglobulin G; virus antibody; wastewater; adult; antibody production; Article; coronavirus disease 2019; cross-sectional study; female; human; infection risk; interpersonal communication; male; Philippines; prevalence; public health; qualitative analysis; quantitative analysis; seroprevalence; trend study; epidemiology; pandemic; seroepidemiology; university; Antibodies; Viral; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Humans; Immunoglobulin G; Pandemics; Prevalence; SARS-CoV-2; Seroepidemiologic Studies; Universities; Wastewater; Wastewater-Based Epidemiological Monitoring; Epidemiology; Infectious Disease; Medical Immunology; Medicine and Health Sciences; Virus Diseases
• 在線閱讀: https://archium.ateneo.edu/asmph-pubs/111; https://archium.ateneo.edu/cgi/viewcontent.cgi?article=1114&context=asmph-pubs

The COVID-19 pandemic has caused a public health emergency in all sectors of society, including universities and other academic institutions. This study determined the seroprevalence of SARS-CoV-2 antibodies among administrators, faculty, staff, and students of a private tertiary academic institution in the Philippines over a 7 month period. It employed a serial cross-sectional method using qualitative and quantitative COVID-19 antibody test kits. A total of 1,318 participants were tested, showing 47.80% of the study population yielding IgG antibodies to SARS-CoV-2 virus. A general increase in seroprevalence was observed from June to December 2021, which coincided with the vaccine roll-out of the country. All brands yielded positive antibody formation, with mRNA vaccines having higher levels than other types of vaccines. A decreasing trend in IgG reactivity was found in vaccinated individuals after 1 to 6 months of completion of the 2 doses of the COVID-19 vaccine. Where possible, IgG and T-cell reactivity and/or neutralizing capacity against SAR-CoV-2 need to be monitored regardless of vaccine brand. Together with uptake of COVID-19 vaccines and boosters, other public health interventions such as wearing of masks and regular testing need to be continued for better protection. Effective communication is also needed to inform risks associated with activities across different settings. Investments in long-term measures such as air filtration and ventilation systems, and wastewater surveillance need to be made.